Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Terns Pharmaceuticals Inc TERN

Healthcare Biotechnology
Terns Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity. Its pipeline includes three clinical-stage development programs: TERN-701, TERN-601 and TERN-501. TERN-701 is its oral, potent, allosteric BCR-ABL tyrosine kinase inhibitors... see more

Recent & Breaking News (NDAQ:TERN)

Terns Pharmaceuticals Appoints Kerry Russell as Chief Medical Officer

GlobeNewswire June 1, 2022

Terns Pharmaceuticals Reports First Quarter 2022 Financial Results and Business Updates

GlobeNewswire May 16, 2022

Terns Pharmaceuticals to Present at the 21st Annual Needham Virtual Healthcare Conference

GlobeNewswire April 4, 2022

Terns Reports Top-line Results from Phase 1 AVIATION Trial of VAP-1 Inhibitor TERN-201

GlobeNewswire March 21, 2022

Terns Pharmaceuticals Reports Fourth Quarter and Full Year 2021 Financial Results and Corporate Highlights

GlobeNewswire March 3, 2022

Terns Pharmaceuticals to Participate in the Cowen 42nd Annual Healthcare Conference

GlobeNewswire February 28, 2022

Terns Pharmaceuticals Appoints Jeffrey R. Jasper, Ph.D., as Senior Vice President, Head of Research and Promotes Diana Chung to Senior Vice President, Chief Development Officer

GlobeNewswire January 6, 2022

Terns Pharmaceuticals to Present at 40th Annual J.P. Morgan Health Care Conference

GlobeNewswire January 3, 2022

Terns Pharmaceuticals Reports Third Quarter 2021 Financial Results and Corporate Highlights

GlobeNewswire November 15, 2021

Terns Pharmaceuticals Highlights Positive Clinical Data from Multiple NASH Programs at AASLD The Liver Meeting® Digital Experience 2021

GlobeNewswire November 12, 2021

Terns Reports Positive Top-line Results from Phase 1 Proof of Concept Clinical Trial of THR-β agonist TERN-501

GlobeNewswire November 9, 2021

Terns Pharmaceuticals to Present Positive Clinical Data on NASH Programs at AASLD The Liver Meeting® Digital Experience 2021

GlobeNewswire October 18, 2021

Terns Pharmaceuticals to Present at H.C. Wainwright 5th Annual NASH Investor Conference

GlobeNewswire October 5, 2021

Terns Appoints Veteran Biopharmaceutical Executive Ann E. Taylor, M.D. to Board of Directors

GlobeNewswire September 28, 2021

Terns Completes Part 1 Enrollment of AVIATION Phase 1b NASH Clinical Trial of VAP-1 Inhibitor TERN-201

GlobeNewswire September 8, 2021

Terns Pharmaceuticals to Present at Upcoming Investor Conferences

GlobeNewswire September 2, 2021

Terns Pharmaceuticals Reports Second Quarter 2021 Financial Results and Corporate Highlights

GlobeNewswire August 16, 2021

Terns Pharmaceuticals to Present at Upcoming Investor Conferences

GlobeNewswire August 3, 2021

Terns Announces Initiation of Patient Dosing in AVIATION Phase 1b NASH Clinical Trial of VAP-1 Inhibitor TERN-201

GlobeNewswire June 24, 2021

Terns Reports Positive Top-line Results from Phase 2a LIFT Study of FXR Agonist TERN-101 in Patients with NASH

GlobeNewswire June 14, 2021